Home
OGN
OGN News

Latest Organon & Co. (OGN) News on November 19, 2025

3 Small-Cap Stocks We Steer Clear Of

StockStory

a month ago

3 Small-Cap Stocks We Steer Clear Of

Is Prolonged Revenue and EPS Decline Altering the Investment Case for Organon (OGN)?

Simply Wall St.

a month ago

Is Prolonged Revenue and EPS Decline Altering the Investment Case for Organon (OGN)?

Organon (OGN) Stock Declines While Market Improves: Some Information for Investors

Zacks

a month ago

Organon (OGN) Stock Declines While Market Improves: Some Information for Investors

Organon (OGN) Dips More Than Broader Market: What You Should Know

Zacks

a month ago

Organon (OGN) Dips More Than Broader Market: What You Should Know

3 Reasons to Avoid OGN and 1 Stock to Buy Instead

StockStory

a month ago

3 Reasons to Avoid OGN and 1 Stock to Buy Instead

Organon (OGN) Outperforms Ahead of Earnings—Is Analyst Optimism Justified Amid Industry Changes?

Simply Wall St.

2 months ago

Organon (OGN) Outperforms Ahead of Earnings—Is Analyst Optimism Justified Amid Industry Changes?

Organon (NYSE:OGN): Assessing Valuation Following Recent Share Price Momentum

Simply Wall St.

2 months ago

Organon (NYSE:OGN): Assessing Valuation Following Recent Share Price Momentum

AbbVie, AMN Healthcare Services, LeMaitre, Waters Corporation, and Organon Shares Skyrocket, What You Need To Know

StockStory

2 months ago

AbbVie, AMN Healthcare Services, LeMaitre, Waters Corporation, and Organon Shares Skyrocket, What You Need To Know

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Zacks

2 months ago

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Why Organon (OGN) Stock Is Trading Up Today

StockStory

2 months ago

Why Organon (OGN) Stock Is Trading Up Today

3 Stocks Under $50 We Find Risky

StockStory

2 months ago

3 Stocks Under $50 We Find Risky

Organon (OGN) Stock Declines While Market Improves: Some Information for Investors

Zacks

2 months ago

Organon (OGN) Stock Declines While Market Improves: Some Information for Investors

Organon (NYSE:OGN) Valuation After FDA Approvals Expand Its Osteoporosis and Bone Health Portfolio

Simply Wall St.

2 months ago

Organon (NYSE:OGN) Valuation After FDA Approvals Expand Its Osteoporosis and Bone Health Portfolio

Organon (OGN) Stock Sinks As Market Gains: What You Should Know

Zacks

5 months ago

Organon (OGN) Stock Sinks As Market Gains: What You Should Know

5 Must-Read Analyst Questions From Organon’s Q1 Earnings Call

StockStory

5 months ago

5 Must-Read Analyst Questions From Organon’s Q1 Earnings Call

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Zacks

5 months ago

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Argus Research

5 months ago

OGN: What does Argus have to say about OGN?

Organon (OGN) Outpaces Stock Market Gains: What You Should Know

Zacks

5 months ago

Organon (OGN) Outpaces Stock Market Gains: What You Should Know

All You Need to Know About Organon (OGN) Rating Upgrade to Buy

Zacks

5 months ago

All You Need to Know About Organon (OGN) Rating Upgrade to Buy

OGN or DOCS: Which Is the Better Value Stock Right Now?

Zacks

5 months ago

OGN or DOCS: Which Is the Better Value Stock Right Now?

Argus Research

5 months ago

OGN: Raising target price to $11.00

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection

Business Wire

6 months ago

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection

Argus Research

6 months ago

OGN: Rating decreased to a HOLD

CEO & Director of Organon Picks Up 14% More Stock

Simply Wall St.

6 months ago

CEO & Director of Organon Picks Up 14% More Stock

Organon (NYSE:OGN) Reports Decreased Earnings Affecting Investor Sentiment

Simply Wall St.

6 months ago

Organon (NYSE:OGN) Reports Decreased Earnings Affecting Investor Sentiment

Organon & Co. (NYSE:OGN) Goes Ex-Dividend Soon

Simply Wall St.

6 months ago

Organon & Co. (NYSE:OGN) Goes Ex-Dividend Soon

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 05/07/2025

Argus Research

6 months ago

OGN: Lowering target price to $10.00

Organon price target lowered to $10 from $11 at BofA

TipRanks

7 months ago

Organon price target lowered to $10 from $11 at BofA

Argus Research

7 months ago

OGN: What does Argus have to say about OGN?

Argus Research

7 months ago

OGN: Lowering target price to $12.00

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors

Business Wire

7 months ago

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors

Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

Business Wire

7 months ago

Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

Argus Research

7 months ago

OGN: Lowering target price to $13.00

Why Organon (OGN) Could Beat Earnings Estimates Again

Zacks

8 months ago

Why Organon (OGN) Could Beat Earnings Estimates Again

Argus Research

8 months ago

OGN: What does Argus have to say about OGN?

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

Business Wire

8 months ago

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Business Wire

8 months ago

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Argus Research

8 months ago

OGN: Lowering target price to $16.00

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

Business Wire

8 months ago

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

Argus Research

9 months ago

OGN: Lowering target price to $15.00

Argus Research

9 months ago

OGN: Raising target price to $17.00

Argus Research

9 months ago

OGN: What does Argus have to say about OGN?

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Simply Wall St.

9 months ago

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Organon Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

9 months ago

Organon Full Year 2024 Earnings: EPS Misses Expectations

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024

Business Wire

9 months ago

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024

Argus Research

9 months ago

OGN: Lowering target price to $16.00

Argus Research

10 months ago

OGN: What does Argus have to say about OGN?

An excellent week for Organon & Co.'s (NYSE:OGN) institutional owners who own 83% as one-year returns inch higher

Simply Wall St.

10 months ago

An excellent week for Organon & Co.'s (NYSE:OGN) institutional owners who own 83% as one-year returns inch higher

Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025

Business Wire

10 months ago

Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025

Argus Research

10 months ago

OGN: What does Argus have to say about OGN?

Argus Research

10 months ago

OGN: What does Argus have to say about OGN?

Argus Research

a year ago

OGN: Lowering target price to $15.00

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire

a year ago

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Argus Research

a year ago

OGN: What does Argus have to say about OGN?

FDA approves Organon’s VTAMA cream, 1% for the treatment for AD

TipRanks

a year ago

FDA approves Organon’s VTAMA cream, 1% for the treatment for AD

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Business Wire

a year ago

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Argus Research

a year ago

OGN: What does Argus have to say about OGN?

Argus Research

a year ago

OGN: Lowering target price to $16.00

Argus Research

a year ago

OGN: Raising target price to $17.00

Argus Research

a year ago

OGN: Rating decreased to a HOLD

Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem

Simply Wall St.

a year ago

Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem

Argus Research

a year ago

OGN: Lowering target price to $18.00

Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Simply Wall St.

a year ago

Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Business Wire

a year ago

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Simply Wall St.

a year ago

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Simply Wall St.

a year ago

Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Organon Reports Results for the Third Quarter Ended September 30, 2024

Business Wire

a year ago

Organon Reports Results for the Third Quarter Ended September 30, 2024

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Business Wire

a year ago

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

GlobeNewswire

a year ago

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Pediatrix Medical Group (MD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

a year ago

Pediatrix Medical Group (MD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a year ago

Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024

Business Wire

a year ago

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024

Argus Research

a year ago

OGN: Lowering target price to $19.00

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

CNW Group

a year ago

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Business Wire

a year ago

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada

CNW Group

a year ago

Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada

Are Options Traders Betting on a Big Move in Organon (OGN) Stock?

Zacks

a year ago

Are Options Traders Betting on a Big Move in Organon (OGN) Stock?

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

GlobeNewswire

a year ago

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Business Wire

a year ago

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Argus Research

a year ago

OGN: What does Argus have to say about OGN?

Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?

Zacks

a year ago

Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?

Argus Research

a year ago

OGN: What does Argus have to say about OGN?

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Business Wire

a year ago

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Investors Shouldn't Be Too Comfortable With Organon's (NYSE:OGN) Earnings

Simply Wall St.

a year ago

Investors Shouldn't Be Too Comfortable With Organon's (NYSE:OGN) Earnings

Organon Second Quarter 2024 Earnings: EPS: US$0.76 (vs US$0.95 in 2Q 2023)

Simply Wall St.

a year ago

Organon Second Quarter 2024 Earnings: EPS: US$0.76 (vs US$0.95 in 2Q 2023)

Organon Reports Results for the Second Quarter Ended June 30, 2024

Business Wire

a year ago

Organon Reports Results for the Second Quarter Ended June 30, 2024

Do Options Traders Know Something About Organon (OGN) Stock We Don't?

Zacks

a year ago

Do Options Traders Know Something About Organon (OGN) Stock We Don't?

Organon & Co. (NYSE:OGN) is largely controlled by institutional shareholders who own 79% of the company

Simply Wall St.

a year ago

Organon & Co. (NYSE:OGN) is largely controlled by institutional shareholders who own 79% of the company

Organon (OGN) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks

a year ago

Organon (OGN) Upgraded to Strong Buy: What Does It Mean for the Stock?

Argus Research

a year ago

OGN: Rating increased to a HOLD

Argus Research

a year ago

OGN: What does Argus have to say about OGN?

Argus Research

a year ago

OGN: What does Argus have to say about OGN?

Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024

Business Wire

a year ago

Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024

Argus Research

a year ago

OGN: What does Argus have to say about OGN?

Do Options Traders Know Something About Organon (OGN) Stock We Don't?

Zacks

a year ago

Do Options Traders Know Something About Organon (OGN) Stock We Don't?

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Business Insider

a year ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women

Insider Monkey

a year ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Reuters

a year ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Insider Monkey

a year ago

Best Date Night Fragrance in 2024

Share on Social Networks: